All In Biotech

Free tool

FAERS Monitor: Ruxience

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761103 or its brand name (Ruxience, Rituximab-Pvvr). Reports on generic versions are filed under their own applications.

Reports

5,245

Serious

4,747

91% of reports

Hospitalization

1,298

Death reported

494

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,152
  • intentional product use issue643
  • condition aggravated628
  • fatigue409
  • death394
  • dyspnoea377
  • covid-19361
  • nausea358
  • inappropriate schedule of product administration355
  • pruritus347
  • headache345
  • throat irritation320
  • malaise307
  • pain302
  • cough293

Reports by year received

View as table
YearReports
20171
20181
202077
2021397
2022771
20231,153
20241,210
20251,092
2026543

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,914 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional product use issueSignal64329.627.617,712
throat irritationSignal32028.825.98,516
off label useSignal2,1529.99.617,862
condition aggravatedSignal6288.37.74,074
covid-19Signal3618.37.52,313
inappropriate schedule of product administrationSignal3557.97.22,151
coughSignal2934.23.8718
pruritusSignal3473.63.3668
malaiseSignal3072.82.5363
dyspnoeaSignal3772.72.4403
headacheSignal3452.22.0233
fatigueSignal4092.11.9246
pain3022.01.8148
death3941.81.7155
nausea3581.81.6135

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.